Rituximab is a generally well-tolerated (Edwards et al., 2004) standard treatment for primary B cell type lymphoma, including CNS lymphoma, rheumatoid arthritis and difficult-to-treat multiple sclerosis where it is administered intravenously twice yearly. The present study sought to investigate ...